Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-11-19 06:44 am Sale | 13D | Trillium Therapeutics Inc. TRIL | Growth Equity Opportunities V LLC | 0 0% | -6,586,363 (Position Closed) | View |
| 2021-11-15 4:35 pm Sale | 13G | Trillium Therapeutics Inc. TRIL | RA CAPITAL MANAGEMENT L.P. | 0 0% | -5,290,481 (Position Closed) | View |
| 2021-08-31 6:43 pm Unchanged | 13D | Trillium Therapeutics Inc. TRIL | Growth Equity Opportunities V LLC | 6,586,363 6.3% | 0 (Unchanged) | View |
| 2021-04-07 4:32 pm Unchanged | 13G | Trillium Therapeutics Inc. TRIL | RA CAPITAL MANAGEMENT L.P. | 5,290,481 5.1% | 0 (Unchanged) | View |
| 2021-02-16 5:17 pm Sale | 13G | Trillium Therapeutics Inc. TRIL | Boxer Capital LLC | 0 0% | -4,425,000 (Position Closed) | View |
| 2021-02-16 4:39 pm Purchase | 13G | Trillium Therapeutics Inc. TRIL | RA CAPITAL MANAGEMENT L.P. | 5,290,481 5.3% | 5,290,481 (New Position) | View |
| 2021-02-16 4:11 pm Purchase | 13G | Trillium Therapeutics Inc. TRIL | Venrock Healthcare Capital Partners III L.P. | 4,040,000 4% | 1,250,000 (+44.80%) | View |
| 2021-02-12 4:30 pm Unchanged | 13G | Trillium Therapeutics Inc. TRIL | Vivo Capital IX LLC | 0 0% | 0 (Unchanged) | View |
| 2021-02-12 08:09 am Purchase | 13G | Trillium Therapeutics Inc. TRIL | Avoro Capital Advisors LLC | 5,800,000 5.7% | 5,800,000 (New Position) | View |
| 2020-05-11 4:13 pm Sale | 13G | Trillium Therapeutics Inc. TRIL | MORGAN STANLEY MS | 1,243,313 1.5% | -626,691 (-33.51%) | View |
| 2020-02-14 4:00 pm Purchase | 13G | Trillium Therapeutics Inc. TRIL | Sio Capital Management LLC | 2,751,186 9.81% | 2,751,186 (New Position) | View |
| 2020-02-14 10:31 am Sale | 13G | Trillium Therapeutics Inc. TRIL | Matrix Capital Management Company LP | 0 0% | -2,288,560 (Position Closed) | View |
| 2020-02-13 2:25 pm Purchase | 13G | Trillium Therapeutics Inc. TRIL | MORGAN STANLEY MS | 1,870,004 6.7% | 220,526 (+13.37%) | View |
| 2020-02-04 5:19 pm Purchase | 13D | Trillium Therapeutics Inc. TRIL | Growth Equity Opportunities V LLC | 6,586,363 8.7% | 4,462,453 (+210.11%) | View |
| 2020-02-03 4:31 pm Purchase | 13G | Trillium Therapeutics Inc. TRIL | Boxer Capital LLC | 4,425,000 5.9% | 4,425,000 (New Position) | View |
| 2020-02-03 4:03 pm Purchase | 13G | TRILLIUM THERAPEUTICS INC SCTPF | Vivo Capital IX LLC | 3,679,060 4.9% | 3,679,060 (New Position) | View |
| 2020-01-21 4:52 pm Purchase | 13G | Trillium Therapeutics Inc. TRIL | Venrock Healthcare Capital Partners III L.P. | 2,790,000 9.95% | 2,790,000 (New Position) | View |
| 2020-01-21 11:27 am Unchanged | 13G | Trillium Therapeutics Inc. TRIL | Empery Asset Management LP | 5,300,000 4.99% | 0 (Unchanged) | View |
| 2019-12-31 4:24 pm Purchase | 13G | Trillium Therapeutics Inc. TRIL | MORGAN STANLEY MS | 1,649,478 5.9% | 1,126,323 (+215.29%) | View |